These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1745 related articles for article (PubMed ID: 19622817)
1. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. Mattsson N; Zetterberg H; Hansson O; Andreasen N; Parnetti L; Jonsson M; Herukka SK; van der Flier WM; Blankenstein MA; Ewers M; Rich K; Kaiser E; Verbeek M; Tsolaki M; Mulugeta E; Rosén E; Aarsland D; Visser PJ; Schröder J; Marcusson J; de Leon M; Hampel H; Scheltens P; Pirttilä T; Wallin A; Jönhagen ME; Minthon L; Winblad B; Blennow K JAMA; 2009 Jul; 302(4):385-93. PubMed ID: 19622817 [TBL] [Abstract][Full Text] [Related]
2. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Hansson O; Zetterberg H; Buchhave P; Londos E; Blennow K; Minthon L Lancet Neurol; 2006 Mar; 5(3):228-34. PubMed ID: 16488378 [TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Buchhave P; Minthon L; Zetterberg H; Wallin AK; Blennow K; Hansson O Arch Gen Psychiatry; 2012 Jan; 69(1):98-106. PubMed ID: 22213792 [TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort. Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Andreasen N; Minthon L; Davidsson P; Vanmechelen E; Vanderstichele H; Winblad B; Blennow K Arch Neurol; 2001 Mar; 58(3):373-9. PubMed ID: 11255440 [TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Riemenschneider M; Lautenschlager N; Wagenpfeil S; Diehl J; Drzezga A; Kurz A Arch Neurol; 2002 Nov; 59(11):1729-34. PubMed ID: 12433260 [TBL] [Abstract][Full Text] [Related]
7. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O; JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367 [TBL] [Abstract][Full Text] [Related]
8. Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Brys M; Pirraglia E; Rich K; Rolstad S; Mosconi L; Switalski R; Glodzik-Sobanska L; De Santi S; Zinkowski R; Mehta P; Pratico D; Saint Louis LA; Wallin A; Blennow K; de Leon MJ Neurobiol Aging; 2009 May; 30(5):682-90. PubMed ID: 17889968 [TBL] [Abstract][Full Text] [Related]
9. Performance of aβ1-40, aβ1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment. Parnetti L; Chiasserini D; Eusebi P; Giannandrea D; Bellomo G; De Carlo C; Padiglioni C; Mastrocola S; Lisetti V; Calabresi P J Alzheimers Dis; 2012; 29(1):229-38. PubMed ID: 22232006 [TBL] [Abstract][Full Text] [Related]
10. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls. Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147 [TBL] [Abstract][Full Text] [Related]
11. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort. Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D; Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532 [TBL] [Abstract][Full Text] [Related]
12. Use of cerebrospinal fluid biomarker analysis for improving Alzheimer's disease diagnosis in a non-specialized setting. Malnar M; Kosicek M; Bene R; Tarnik IP; Pavelin S; Babic I; Brajenovic-Milic B; Hecimovic H; Titlic M; Trkanjec Z; Demarin I; Hecimovic S Acta Neurobiol Exp (Wars); 2012; 72(3):264-71. PubMed ID: 23093013 [TBL] [Abstract][Full Text] [Related]
14. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia. Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593 [TBL] [Abstract][Full Text] [Related]
15. CSF soluble amyloid precursor proteins in the diagnosis of incipient Alzheimer disease. Perneczky R; Tsolakidou A; Arnold A; Diehl-Schmid J; Grimmer T; Förstl H; Kurz A; Alexopoulos P Neurology; 2011 Jul; 77(1):35-8. PubMed ID: 21700579 [TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid biomarkers for Alzheimer’s disease: diagnostic performance in a homogeneous mono-center population. Johansson P; Mattsson N; Hansson O; Wallin A; Johansson JO; Andreasson U; Zetterberg H; Blennow K; Svensson J J Alzheimers Dis; 2011; 24(3):537-46. PubMed ID: 21297262 [TBL] [Abstract][Full Text] [Related]
17. CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease. Chiasserini D; Parnetti L; Andreasson U; Zetterberg H; Giannandrea D; Calabresi P; Blennow K J Alzheimers Dis; 2010; 22(4):1281-8. PubMed ID: 20930282 [TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid profiles and prospective course and outcome in patients with amnestic mild cognitive impairment. Okonkwo OC; Mielke MM; Griffith HR; Moghekar AR; O'Brien RJ; Shaw LM; Trojanowski JQ; Albert MS; Arch Neurol; 2011 Jan; 68(1):113-9. PubMed ID: 21220682 [TBL] [Abstract][Full Text] [Related]
19. Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer's disease dementia in mild cognitive impairment. Baldeiras I; Santana I; Leitão MJ; Gens H; Pascoal R; Tábuas-Pereira M; Beato-Coelho J; Duro D; Almeida MR; Oliveira CR Alzheimers Res Ther; 2018 Mar; 10(1):33. PubMed ID: 29558986 [TBL] [Abstract][Full Text] [Related]
20. CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Ritchie C; Smailagic N; Noel-Storr AH; Ukoumunne O; Ladds EC; Martin S Cochrane Database Syst Rev; 2017 Mar; 3(3):CD010803. PubMed ID: 28328043 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]